Eptifibatide in Endovascular Treatment of Acute Ischemic Stroke (EPOCH)

• Status: Unknown status
• Trial end date: 2020-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The study is a single-arm, open-label, multicenter clinical trial.The primary purpose of this trial is to evaluate the incidence of symptomatic intracranial hemorrhage in patients with acute ischemic stroke within 48 hours after the use of Eptifibatide injection. Patients with acute ischemic stroke treated with intravascular thrombolytic therapy, mechanical thrombolysis, angioplasty and so on were treated with Eptifibatide injection on the first day, followed by the second day, the third day, the discharge day and the 90 days.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ministry of Science and Technology of the People´s Republic of China
• Treatments: Eptifibatide

Criteria

Inclusion Criteria:

1. Age≥18 years.

2. Acute ischemic stroke.

3. Treated with endovascular treatment, including intra-arterial thrombolysis, mechanical thrombectomy, and angioplasty.

4. Written informed consent obtained from patient or patient's legally authorized representative.

Exclusion Criteria:

1. Failed to vascular recanalization (mTICI≤1).

2. Diagnosis of intracranial hemorrhagic disease, such as intracranial hemorrhage, subarachnoid hemorrhage and so on.

3. Known coagulopathy, Systemic Bleeding Tendency, or baseline platelet count < 100000/mm3.

4. History of chronic hepatopathy, liver and kidney dysfunction, elevating ALT (> 3 times normal upper limit), elevating serum creatinine (> 2 times normal upper limit).

5. Patients with severe hypertension (systolic blood pressure > 200mmHg or diastolic blood pressure > 110mmHg).

6. Known drug or food allergy.

7. Used other Glycoprotein IIb/IIIa receptor antagonists.

8. Contraindications for DSA, severe contrast media allergy or iodine contrast media absolute contraindications.

9. Childbearing age women whose pregnancy tests were negative refused to take effective contraception. Pregnant or lactating or positive pregnancy test on admission.

10. Incapable to follow this study for mental illness, cognitive or emotional disorder.

11. The researchers do not consider the participants appropriate to get into this study.